Latest news with #SAN DIEGO
Yahoo
a day ago
- Business
- Yahoo
MedImpact Offers Low Cost, Unbranded Ustekinumab-aekn Biosimilar to Any Specialty Pharmacy in the US
SAN DIEGO, August 18, 2025--(BUSINESS WIRE)--MedImpact Holdings Inc. today announced that it will have access to an unbranded biosimilar ustekinumab-aekn at a significantly lower cost than the reference Stelara® (ustekinumab). The biosimilar, distributed by Anda, an affiliate of Teva Pharmaceuticals USA, Inc., will be available for direct purchase from MedImpact's preferred partner, Birdi, Inc., by any licensed specialty pharmacy. "Today, a drug's cost rises at each step in the supply chain," said Arpit Patel, MedImpact Senior Vice President of Trade Relations and Supply Chain. "We designed our unbranded strategy to bypass these costs to deliver far greater value to pharmacies and payers, and a more affordable treatment option for patients." As specialty drug costs continue to rise and pharmacies continue to close, MedImpact's unbranded biosimilar strategy provides specialty pharmacies with a new sourcing option and access to lower prices. It also gives payers across healthcare—and not just MedImpact clients—greater flexibility, choice, and control over one of their greatest cost drivers. As part of a broader move to reduce the industry's reliance on rebates and enhance price transparency, payers and members will gain access to the low cost at the point of sale. By using an FDA-designated interchangeable biosimilar purchased from Anda, an affiliate of Teva Pharmaceuticals USA, Inc., a company with proven biosimilar expertise, this strategy is expected to drive increased physician prescribing and enhanced patient acceptance, and ultimately deliver meaningful cost savings. "MedImpact's specialty strategy is deeply rooted in the principle that pharmacies, members, and payers should not have to compromise access for affordability, and this strategy delivers on that promise," said Patel. "The unbranded ustekinumab-aekn, an interchangeable biosimilar to the reference drug Stelara®, is the first of many products we will be providing to expand access, drive affordability, and transform the specialty drug market." The unbranded ustekinumab-aekn biosimilar is expected to be available for purchase on January 01, 2026. To learn more about the unbranded ustekinumab-aekn biosimilar, please contact info@ About MedImpact San Diego-based MedImpact Healthcare Systems, Inc. is the nation's largest independent health solutions, technology, and pharmacy benefit management provider. For 35 years, MedImpact has helped commercial and government healthcare payers improve member health, manage benefits, and reduce drug costs. Today, MedImpact serves more than 20 million members and processes more than $40 billion in pharmacy transactions annually. To learn more, visit us online, follow us on LinkedIn, or contact us at info@ View source version on Contacts Jennifer Kroll, jkroll@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-08-2025
- Business
- Yahoo
Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference
SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in a panel discussion and corporate presentation at the H.C. Wainwright Annual Ophthalmology Virtual Conference on August 13, 2025. Details of the presentations are as follows: 7:00 am ET, on-demand corporate presentation 11:00 am ET, 'Pivotal-Stage Assets for Retinal Disorders' panel discussion Webcast Link InstructionsA webcast of each presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: The replays will be archived for 90 days following the presentation date. About Belite BioBelite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite's lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at Media and Investor Relations Contact:Jennifer Wu ir@ Julie Fallonbelite@
Associated Press
11-08-2025
- Business
- Associated Press
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the second quarter ended June 30, 2025, and provided a general business update. 'This quarter, we remained on track with the strategic objectives we outlined at the start of the year, including the completion of enrollment in our pivotal Phase 3 PHOENIX trial — an important milestone in our development efforts for people living with geographic atrophy,' said Dr. Tom Lin, Chairman and CEO of Belite Bio. 'We also received Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease from the FDA, underscoring its potential as the first-ever treatment for this patient population and acknowledging the significant unmet need for people living with this debilitating disease. With the DRAGON trial on track to complete by the end of this year, we remain focused on advancing Tinlarebant toward key clinical and regulatory milestones.' Second Quarter 2025 Business Highlights and Upcoming Milestones: Clinical Highlights Tinlarebant (LBS-008) is an oral, potent, once-daily, retinol binding protein 4 (RBP4) antagonist that decreases RBP4 levels in the blood and reduces vitamin A (retinol) delivery to the eye without disrupting systemic retinol delivery to other tissues. Vitamin A is critical for normal vision but can accumulate as toxic byproducts in individuals affected with STGD1 and GA, the advanced form of dry age-related macular degeneration (AMD), leading to retinal cell death and loss of vision. Corporate Highlights Second Quarter 2025 Financial Results: Current Assets: As of June 30, 2025, the Company had $149.2 million in cash, liquidity funds, time deposits, and U.S treasury bills. R&D Expenses: For the three months ended June 30, 2025, research and development expenses were $11.0 million compared to $9.1 million for the same period in 2024. For the six months ended June 30, 2025, research and development expenses were $20.4 million compared to $15.8 million for the same period in 2024. The increase in research and development expenses in both the quarter and year-to-date was primarily attributable to (i) higher pass-through expenses related to the PHOENIX trial and manufacturing expenses payments, partially offset by lower DRAGON trial expenses and a development milestone payment for the completion of a phase 2 trial in 2024; (ii) an increase in share-based compensation expenses. G&A Expenses: For the three months ended June 30, 2025, general and administrative expenses were $6.5 million compared to $1.4 million for the same period in 2024. For the six months ended June 30, 2025, general and administration expenses were $12.7 million compared to $3.0 million for the same period in 2024. The increase in general and administrative expenses in both the quarter and year-to-date was primarily due to an increase in share-based compensation expenses. Other Income: For the three months ended June 30, 2025, other income was $1.3 million compared to $1.0 million for the same period in 2024. For the six months ended June 30, 2025, other income was $2.5 million compared to $1.4 million for the same period in 2024. The increase in both the quarter and year-to-date was attributed to interest from time deposits and U.S. treasury bills. Net Loss: For the three months ended June 30, 2025, the Company reported a net loss of $16.3 million, compared to a net loss of $9.5 million for the same period in 2024. For the six months ended June 30, 2025, the Company reported a net loss of $30.6 million, compared to a net loss of $17.4 million for the same period in 2024. Webcast Information Belite Bio will host a webcast on Monday, August 11, 2025, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update. To join the webcast, please visit A replay will be available for approximately 90 days following the event. About Belite Bio Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite's lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at Important Cautions Regarding Forward Looking Statements This press release contains forward-looking statements about future expectations and plans, as well as other statements regarding matters that are not historical facts. These statements include but are not limited to statements regarding the potential implications of clinical data for patients, and Belite Bio's advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates, and any other statements containing the words 'expect', 'hope' and similar expressions. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Belite Bio's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the timing to complete relevant clinical trials and/or to receive the interim/final data of such clinical trials; the timing to submit trial data to regulatory authorities for drug approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Belite Bio's drug candidates; the potential efficacy of Tinlarebant, as well as those risks more fully discussed in the 'Risk Factors' section in Belite Bio's filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Belite Bio, and Belite Bio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Media and Investor Relations Contact: Jennifer Wu [email protected] Julie Fallon [email protected]
Yahoo
08-08-2025
- Business
- Yahoo
Turtle Beach Corporation to Participate in Oppenheimer 28th Annual Technology, Internet & Communications Conference
SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Turtle Beach Corporation (Nasdaq: TBCH, the 'Company'), a leading gaming accessories brand, today announced that Cris Keirn, Chief Executive Officer, and Mark Weinswig, Chief Financial Officer, will virtually participate in the Oppenheimer 28th Annual Technology, Internet & Communications Conference. Chief Executive Officer Cris Keirn will host a fireside chat on Tuesday, August 12 at 2:55 p.m. ET, and management will also be available for meetings during the conference. A live webcast of the event will be available through the 'Events & Presentations' section of TBCH's website at A replay of the webcast will be available on the investor relations website for 90 days. About Turtle Beach CorporationTurtle Beach Corporation (the 'Company') ( is one of the world's leading gaming accessory providers. The Company's namesake Turtle Beach brand ( is known for designing best-selling gaming headsets, top-rated game controllers, award-winning PC gaming peripherals, and groundbreaking gaming simulation accessories. Innovation, first-to-market features, a broad range of products for all types of gamers, and top-rated customer support have made Turtle Beach a fan-favorite brand and the market leader in console gaming audio for over a decade. Turtle Beach Corporation acquired Performance Designed Products LLC ( in 2024. Turtle Beach's shares are traded on the Nasdaq Exchange under the symbol: TBCH. Cautionary Note on Forward-Looking StatementsThis press release includes forward-looking information and statements within the meaning of the federal securities laws. Except for historical information contained in this release, statements in this release may constitute forward-looking statements regarding assumptions, projections, expectations, targets, intentions, or beliefs about future events. Statements containing the words 'may,' 'could,' 'would,' 'should,' 'believe,' 'expect,' 'anticipate,' 'plan,' 'estimate,' 'target,' 'goal,' 'project,' 'intend' and similar expressions, or the negatives thereof, constitute forward-looking statements. Forward-looking statements are only predictions and are not guarantees of performance. Forward-looking statements in this press release include, but are not limited to, statements regarding potential share repurchases by the Company and the potential refinancing of the Company's outstanding loan balance. Forward-looking statements involve known and unknown risks and uncertainties, which could cause actual results to differ materially from those contained in any forward-looking statement. The inclusion of such information should not be regarded as a representation by the Company, or any person, that the objectives of the Company will be achieved. Forward-looking statements are based on management's current beliefs and expectations, as well as assumptions made by, and information currently available to, management. While the Company believes that its expectations are based upon reasonable assumptions, there can be no assurances that its goals and strategy will be realized. Numerous factors, including risks and uncertainties, may affect actual results and may cause results to differ materially from those expressed in forward-looking statements made by the Company or on its behalf. Some of these factors include, but are not limited to, our ability to refinance our indebtedness on terms favorable to the Company, trade policies, including the imposition of tariffs on imported goods and other trade restrictions, the release and availability of successful game titles, macroeconomic conditions affecting the demand for our products, logistic and supply chain challenges and costs, dependence on the success and availability of third-parties to manufacture and manage the logistics of transporting and distributing our products, the substantial uncertainties inherent in the acceptance of existing and future products, the difficulty of commercializing and protecting new technology, the impact of competitive products and pricing, general business and economic conditions, risks associated with the expansion of our business including the integration of any businesses we acquire and the integration of such businesses within our internal control over financial reporting and operations, our indebtedness, liquidity, and other factors discussed in our public filings, including the risk factors included in the Company's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and the Company's other periodic reports filed with the SEC. Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, the Company is under no obligation to publicly update or revise any forward-looking statement after the date of this release whether as a result of new information, future developments or otherwise. CONTACTS Investors:tbch@ Public Relations & Media:MacLean MarshallSr. Director, Global CommunicationsTurtle Beach Corporation(858) in to access your portfolio
Yahoo
08-08-2025
- Business
- Yahoo
Turtle Beach Corporation to Participate in Oppenheimer 28th Annual Technology, Internet & Communications Conference
SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Turtle Beach Corporation (Nasdaq: TBCH, the 'Company'), a leading gaming accessories brand, today announced that Cris Keirn, Chief Executive Officer, and Mark Weinswig, Chief Financial Officer, will virtually participate in the Oppenheimer 28th Annual Technology, Internet & Communications Conference. Chief Executive Officer Cris Keirn will host a fireside chat on Tuesday, August 12 at 2:55 p.m. ET, and management will also be available for meetings during the conference. A live webcast of the event will be available through the 'Events & Presentations' section of TBCH's website at A replay of the webcast will be available on the investor relations website for 90 days. About Turtle Beach CorporationTurtle Beach Corporation (the 'Company') ( is one of the world's leading gaming accessory providers. The Company's namesake Turtle Beach brand ( is known for designing best-selling gaming headsets, top-rated game controllers, award-winning PC gaming peripherals, and groundbreaking gaming simulation accessories. Innovation, first-to-market features, a broad range of products for all types of gamers, and top-rated customer support have made Turtle Beach a fan-favorite brand and the market leader in console gaming audio for over a decade. Turtle Beach Corporation acquired Performance Designed Products LLC ( in 2024. Turtle Beach's shares are traded on the Nasdaq Exchange under the symbol: TBCH. Cautionary Note on Forward-Looking StatementsThis press release includes forward-looking information and statements within the meaning of the federal securities laws. Except for historical information contained in this release, statements in this release may constitute forward-looking statements regarding assumptions, projections, expectations, targets, intentions, or beliefs about future events. Statements containing the words 'may,' 'could,' 'would,' 'should,' 'believe,' 'expect,' 'anticipate,' 'plan,' 'estimate,' 'target,' 'goal,' 'project,' 'intend' and similar expressions, or the negatives thereof, constitute forward-looking statements. Forward-looking statements are only predictions and are not guarantees of performance. Forward-looking statements in this press release include, but are not limited to, statements regarding potential share repurchases by the Company and the potential refinancing of the Company's outstanding loan balance. Forward-looking statements involve known and unknown risks and uncertainties, which could cause actual results to differ materially from those contained in any forward-looking statement. The inclusion of such information should not be regarded as a representation by the Company, or any person, that the objectives of the Company will be achieved. Forward-looking statements are based on management's current beliefs and expectations, as well as assumptions made by, and information currently available to, management. While the Company believes that its expectations are based upon reasonable assumptions, there can be no assurances that its goals and strategy will be realized. Numerous factors, including risks and uncertainties, may affect actual results and may cause results to differ materially from those expressed in forward-looking statements made by the Company or on its behalf. Some of these factors include, but are not limited to, our ability to refinance our indebtedness on terms favorable to the Company, trade policies, including the imposition of tariffs on imported goods and other trade restrictions, the release and availability of successful game titles, macroeconomic conditions affecting the demand for our products, logistic and supply chain challenges and costs, dependence on the success and availability of third-parties to manufacture and manage the logistics of transporting and distributing our products, the substantial uncertainties inherent in the acceptance of existing and future products, the difficulty of commercializing and protecting new technology, the impact of competitive products and pricing, general business and economic conditions, risks associated with the expansion of our business including the integration of any businesses we acquire and the integration of such businesses within our internal control over financial reporting and operations, our indebtedness, liquidity, and other factors discussed in our public filings, including the risk factors included in the Company's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and the Company's other periodic reports filed with the SEC. Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, the Company is under no obligation to publicly update or revise any forward-looking statement after the date of this release whether as a result of new information, future developments or otherwise. CONTACTS Investors:tbch@ Public Relations & Media:MacLean MarshallSr. Director, Global CommunicationsTurtle Beach Corporation(858) in to access your portfolio
